En ny och bättre test för tuberkulos

The purpose of this project is todetermine how mycobacterial glycolipid lipoarabinomannan (LAM) and its precursor phosphatidyl-myo-inositol mannoside (PIM)can be used for the identification and follow up of patients with active and latent tuberculosis (TB).

Tests to rapidly provide information useful for the clinical management in different clinical settings will be developed and evaluated.Our aims are:To determine the performance of a new prototype of our urinary LAM test for: i) the diagnosis of active TB; and ii) to identify patients with LTB at high risk of developing active TB.To define new diagnostic biomarkers based on LAM and PIM to detect patients with latent TB and identify those who will progress to active TB.Achieving these aims will improve rapid diagnosis, early treatment initiation and reduce transmission which will reduce patient suffering and is absolutely needed to fulfill the WHO and Agenda 2030 goals of eliminating TB.